schliessen

Filtern

 

Bibliotheken

Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy.

BACKGROUNDMyelofibrosis is associated historically with a poor prognosis in patients with chronic myelogenous leukemia (CML). Its significance in the recent era of effective therapy with imatinib mesylate is unknown. METHODSThe current study evaluated the significance of the degree of pretreatment m... Full description

Journal Title: Cancer August 15, 2005, Vol.104(4), pp.777-780
Main Author: Kantarjian, Hagop M
Other Authors: Bueso-Ramos, Carlos E , Talpaz, Moshe , O'Brien, Susan , Giles, Francis , Faderl, Stefan , Wierda, William , Rios, Mary Beth , Shan, Jianqin , Cortes, Jorge
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 0008-543X
Link: http://search.proquest.com/docview/68451683/?pq-origsite=primo
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: proquest68451683
title: Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy.
format: Article
creator:
  • Kantarjian, Hagop M
  • Bueso-Ramos, Carlos E
  • Talpaz, Moshe
  • O'Brien, Susan
  • Giles, Francis
  • Faderl, Stefan
  • Wierda, William
  • Rios, Mary Beth
  • Shan, Jianqin
  • Cortes, Jorge
subjects:
  • Adolescent–Therapeutic Use
  • Adult–Complications
  • Aged–Drug Therapy
  • Aged, 80 and Over–Mortality
  • Antineoplastic Agents–Therapeutic Use
  • Benzamides–Drug Therapy
  • Female–Etiology
  • Humans–Therapeutic Use
  • Imatinib Mesylate–Therapeutic Use
  • Leukemia, Myeloid, Chronic-Phase–Therapeutic Use
  • Male–Therapeutic Use
  • Middle Aged–Therapeutic Use
  • Piperazines–Therapeutic Use
  • Primary Myelofibrosis–Therapeutic Use
  • Prognosis–Therapeutic Use
  • Pyrimidines–Therapeutic Use
  • Survival Analysis–Therapeutic Use
  • Abridged
  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate
ispartof: Cancer, August 15, 2005, Vol.104(4), pp.777-780
description: BACKGROUNDMyelofibrosis is associated historically with a poor prognosis in patients with chronic myelogenous leukemia (CML). Its significance in the recent era of effective therapy with imatinib mesylate is unknown. METHODSThe current study evaluated the significance of the degree of pretreatment myelofibrosis on response and survival with imatinib therapy in patients with newly diagnosed CML. The study group comprised 198 patients with newly diagnosed Philadelphia chromosome-positive, chronic-phase CML treated with imatinib mesylate therapy. They were analyzed for the prognostic significance of bone marrow reticulin fibrosis. RESULTSSevere reticulin (Grade 3-4) fibrosis was observed in 75 patients (38%): Grade 3 in 46 (23%) patients and Grade 4 in 29 (15%) patients. There was a trend towards a lower incidence of a complete cytogenetic response in patients with Grade 4 reticulin fibrosis (76% vs. 89%; P = 0.07), and a significantly worse survival (estimated 3-year survival rate of 87% vs. 97%; P = 0.04). CONCLUSIONSAlthough the prognostic significance of severe reticulin fibrosis in patients with newly diagnosed CML receiving imatinib therapy was better, 15% of patients with Grade 4 reticulin fibrosis still had a worse outcome.
language: eng
source:
identifier: ISSN: 0008-543X
fulltext: fulltext
issn:
  • 0008543X
  • 0008-543X
url: Link


@attributes
ID855916908
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid68451683
sourceidproquest
recordidTN_proquest68451683
sourcesystemOther
pqid68451683
galeid138922025
display
typearticle
titleSignificance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy.
creatorKantarjian, Hagop M ; Bueso-Ramos, Carlos E ; Talpaz, Moshe ; O'Brien, Susan ; Giles, Francis ; Faderl, Stefan ; Wierda, William ; Rios, Mary Beth ; Shan, Jianqin ; Cortes, Jorge
contributorKantarjian, Hagop M (correspondence author) ; Kantarjian, Hagop M (record owner)
ispartofCancer, August 15, 2005, Vol.104(4), pp.777-780
identifierISSN: 0008-543X
subjectAdolescent–Therapeutic Use ; Adult–Complications ; Aged–Drug Therapy ; Aged, 80 and Over–Mortality ; Antineoplastic Agents–Therapeutic Use ; Benzamides–Drug Therapy ; Female–Etiology ; Humans–Therapeutic Use ; Imatinib Mesylate–Therapeutic Use ; Leukemia, Myeloid, Chronic-Phase–Therapeutic Use ; Male–Therapeutic Use ; Middle Aged–Therapeutic Use ; Piperazines–Therapeutic Use ; Primary Myelofibrosis–Therapeutic Use ; Prognosis–Therapeutic Use ; Pyrimidines–Therapeutic Use ; Survival Analysis–Therapeutic Use ; Abridged ; Antineoplastic Agents ; Benzamides ; Piperazines ; Pyrimidines ; Imatinib Mesylate
descriptionBACKGROUNDMyelofibrosis is associated historically with a poor prognosis in patients with chronic myelogenous leukemia (CML). Its significance in the recent era of effective therapy with imatinib mesylate is unknown. METHODSThe current study evaluated the significance of the degree of pretreatment myelofibrosis on response and survival with imatinib therapy in patients with newly diagnosed CML. The study group comprised 198 patients with newly diagnosed Philadelphia chromosome-positive, chronic-phase CML treated with imatinib mesylate therapy. They were analyzed for the prognostic significance of bone marrow reticulin fibrosis. RESULTSSevere reticulin (Grade 3-4) fibrosis was observed in 75 patients (38%): Grade 3 in 46 (23%) patients and Grade 4 in 29 (15%) patients. There was a trend towards a lower incidence of a complete cytogenetic response in patients with Grade 4 reticulin fibrosis (76% vs. 89%; P = 0.07), and a significantly worse survival (estimated 3-year survival rate of 87% vs. 97%; P = 0.04). CONCLUSIONSAlthough the prognostic significance of severe reticulin fibrosis in patients with newly diagnosed CML receiving imatinib therapy was better, 15% of patients with Grade 4 reticulin fibrosis still had a worse outcome.
languageeng
source
version6
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
backlink$$Uhttp://search.proquest.com/docview/68451683/?pq-origsite=primo$$EView_record_in_ProQuest_(subscribers_only)
search
creatorcontrib
0Kantarjian, Hagop M
1Bueso-Ramos, Carlos E
2Talpaz, Moshe
3O'Brien, Susan
4Giles, Francis
5Faderl, Stefan
6Wierda, William
7Rios, Mary Beth
8Shan, Jianqin
9Cortes, Jorge
titleSignificance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy.
descriptionBACKGROUNDMyelofibrosis is associated historically with a poor prognosis in patients with chronic myelogenous leukemia (CML). Its significance in the recent era of effective therapy with imatinib mesylate is unknown. METHODSThe current study evaluated the significance of the degree of pretreatment myelofibrosis on response and survival with imatinib therapy in patients with newly diagnosed CML. The study group comprised 198 patients with newly diagnosed Philadelphia chromosome-positive, chronic-phase CML treated with imatinib mesylate therapy. They were analyzed for the prognostic significance of bone marrow reticulin fibrosis. RESULTSSevere reticulin (Grade 3-4) fibrosis was observed in 75 patients (38%): Grade 3 in 46 (23%) patients and Grade 4 in 29 (15%) patients. There was a trend towards a lower incidence of a complete cytogenetic response in patients with Grade 4 reticulin fibrosis (76% vs. 89%; P = 0.07), and a significantly worse survival (estimated 3-year survival rate of 87% vs. 97%; P = 0.04). CONCLUSIONSAlthough the prognostic significance of severe reticulin fibrosis in patients with newly diagnosed CML receiving imatinib therapy was better, 15% of patients with Grade 4 reticulin fibrosis still had a worse outcome.
subject
0Adolescent–Therapeutic Use
1Adult–Complications
2Aged–Drug Therapy
3Aged, 80 and Over–Mortality
4Antineoplastic Agents–Therapeutic Use
5Benzamides–Drug Therapy
6Female–Etiology
7Humans–Therapeutic Use
8Imatinib Mesylate–Therapeutic Use
9Leukemia, Myeloid, Chronic-Phase–Therapeutic Use
10Male–Therapeutic Use
11Middle Aged–Therapeutic Use
12Piperazines–Therapeutic Use
13Primary Myelofibrosis–Therapeutic Use
14Prognosis–Therapeutic Use
15Pyrimidines–Therapeutic Use
16Survival Analysis–Therapeutic Use
17Abridged
18Antineoplastic Agents
19Benzamides
20Piperazines
21Pyrimidines
22Imatinib Mesylate
general
0English
1MEDLINE (ProQuest)
2ProQuest Biological Science Collection
3ProQuest Natural Science Collection
4ProQuest SciTech Collection
5Biological Science Database
6Natural Science Collection
7SciTech Premium Collection
8Health Research Premium Collection
9Health Research Premium Collection (Alumni edition)
sourceidproquest
recordidproquest68451683
issn
00008543X
10008-543X
rsrctypearticle
creationdate2005
addtitleCancer
searchscope
01007527
11007944
210000004
310000038
410000050
510000120
610000159
710000238
810000253
910000260
1010000270
1110000271
1210000302
13proquest
scope
01007527
11007944
210000004
310000038
410000050
510000120
610000159
710000238
810000253
910000260
1010000270
1110000271
1210000302
13proquest
lsr43
01007527false
11007944false
210000004false
310000038false
410000050false
510000120false
610000159false
710000238false
810000253false
910000260false
1010000270false
1110000271false
1210000302false
contributorKantarjian, Hagop M
startdate20050815
enddate20050815
citationpf 777 pt 780 vol 104 issue 4
lsr30VSR-Enriched:[doi, galeid, pqid, eissn]
sort
titleSignificance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy.
authorKantarjian, Hagop M ; Bueso-Ramos, Carlos E ; Talpaz, Moshe ; O'Brien, Susan ; Giles, Francis ; Faderl, Stefan ; Wierda, William ; Rios, Mary Beth ; Shan, Jianqin ; Cortes, Jorge
creationdate20050815
lso0120050815
facets
frbrgroupid2533303034453833505
frbrtype5
newrecords20181218
languageeng
creationdate2005
topic
0Adolescent–Therapeutic Use
1Adult–Complications
2Aged–Drug Therapy
3Aged, 80 and Over–Mortality
4Antineoplastic Agents–Therapeutic Use
5Benzamides–Drug Therapy
6Female–Etiology
7Humans–Therapeutic Use
8Imatinib Mesylate–Therapeutic Use
9Leukemia, Myeloid, Chronic-Phase–Therapeutic Use
10Male–Therapeutic Use
11Middle Aged–Therapeutic Use
12Piperazines–Therapeutic Use
13Primary Myelofibrosis–Therapeutic Use
14Prognosis–Therapeutic Use
15Pyrimidines–Therapeutic Use
16Survival Analysis–Therapeutic Use
17Abridged
18Antineoplastic Agents
19Benzamides
20Piperazines
21Pyrimidines
22Imatinib Mesylate
collection
0MEDLINE (ProQuest)
1ProQuest Biological Science Collection
2ProQuest Natural Science Collection
3ProQuest SciTech Collection
4Biological Science Database
5Natural Science Collection
6SciTech Premium Collection
7Health Research Premium Collection
8Health Research Premium Collection (Alumni edition)
prefilterarticles
rsrctypearticles
creatorcontrib
0Kantarjian, Hagop M
1Bueso-Ramos, Carlos E
2Talpaz, Moshe
3O'Brien, Susan
4Giles, Francis
5Faderl, Stefan
6Wierda, William
7Rios, Mary Beth
8Shan, Jianqin
9Cortes, Jorge
jtitleCancer
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Kantarjian
1Bueso-Ramos
2Talpaz
3O'Brien
4Giles
5Faderl
6Wierda
7Rios
8Shan
9Cortes
aufirst
0Hagop M
1Carlos E
2Moshe
3Susan
4Francis
5Stefan
6William
7Mary Beth
8Jianqin
9Jorge
au
0Kantarjian, Hagop M
1Bueso-Ramos, Carlos E
2Talpaz, Moshe
3O'Brien, Susan
4Giles, Francis
5Faderl, Stefan
6Wierda, William
7Rios, Mary Beth
8Shan, Jianqin
9Cortes, Jorge
addauKantarjian, Hagop M
atitleSignificance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy.
jtitleCancer
risdate20050815
volume104
issue4
spage777
epage780
pages777-780
issn0008-543X
formatjournal
genrearticle
ristypeJOUR
abstractBACKGROUNDMyelofibrosis is associated historically with a poor prognosis in patients with chronic myelogenous leukemia (CML). Its significance in the recent era of effective therapy with imatinib mesylate is unknown. METHODSThe current study evaluated the significance of the degree of pretreatment myelofibrosis on response and survival with imatinib therapy in patients with newly diagnosed CML. The study group comprised 198 patients with newly diagnosed Philadelphia chromosome-positive, chronic-phase CML treated with imatinib mesylate therapy. They were analyzed for the prognostic significance of bone marrow reticulin fibrosis. RESULTSSevere reticulin (Grade 3-4) fibrosis was observed in 75 patients (38%): Grade 3 in 46 (23%) patients and Grade 4 in 29 (15%) patients. There was a trend towards a lower incidence of a complete cytogenetic response in patients with Grade 4 reticulin fibrosis (76% vs. 89%; P = 0.07), and a significantly worse survival (estimated 3-year survival rate of 87% vs. 97%; P = 0.04). CONCLUSIONSAlthough the prognostic significance of severe reticulin fibrosis in patients with newly diagnosed CML receiving imatinib therapy was better, 15% of patients with Grade 4 reticulin fibrosis still had a worse outcome.
urlhttp://search.proquest.com/docview/68451683/
doi10.1002/cncr.21235
eissn10970142
date2005-08-15